Assessing post-treatment immune profile changes in metastatic kidney cancer

Post-therapy biopsies reveal divergent immune microenvironments by treatment type

INDICATION
Kidney
BIOMARKER
IPS

Violin plots compare IPS% distributions between old and new standard of care therapies.
Immune Profile Score (IPS) values among patients with Kidney cancer by treatment type in pre-treatment (A) and post-treatment (B) biopsies. Patients treated with Axitinib + Pembrolizumab are shown in blue, while those treated with Ipilimumab + Nivolumab are shown in black. The Wilcoxon rank sum test p-value is depicted.

Related cases

Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Unable to determine image content.

Evaluating MTAP deletion and immune profile scores to identify unmet needs in solid tumors

2026-07-01
IPS
MTAP
Pan-Cancer
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
A grid of small orange squares with varying shades forming abstract lines and clusters.

Impact of M2-like macrophage infiltration on RCC immunotherapy outcomes

2026-03-27
Kidney
M2
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Light purple dots forming a stylized bar chart on a white background, showing data patterns.

Investigating LAG-3 expression as a biomarker in mRCC with multimodal data

2026-01-20
Kidney
LAG3